Roll-out of a universal childhood COVID-19 vaccine programme for 12-15 year olds in Northern Ireland

Abstract

Abstract On 3rd September 2021 the UK Chief Medical Officers (CMOs) jointly published a recommendation that all children aged 12-15 years be offered the COVID-19 vaccine. They concluded that, further to the minimal advantage at individual level for this age group, vaccination would likely help reduce transmission within schools, thus providing a sufficient extra advantage necessary to introduce the programme. In recommending this to Ministers, UK CMOs recognised that the overwhelming benefits of vaccination for adults were not as clear-cut for young people aged 12-15. Children, young people and their parents would need to understand potential benefits, potential side effects and the balance between them. The roll out of the programme had to be undertaken at pace. In NI it was decided that the school setting would be the optimum delivery location as it maximises uptake and reduces inequalities in uptake. A multi-agency project implementation group was formed. The vaccine programme was delivered between October-December 2021, and it brought unique challenges, including; safety concerns around a new vaccine; delays in policy announcements; creation of public and professional resources with complex evidence; anti-vax sentiment and security issues; scale and pace of rollout; and communication with multiple stakeholders. Engagement with schools and teaching unions was crucial, with bespoke support resources developed to aid this. This unique implementation process highlighted the success of the existing school-based vaccine delivery model in NI. It provided opportunities to work closely with education colleagues, and to develop innovative materials for communication of balanced public health messages to a variety of audiences. It also presented unique challenges such as anti-vax discourse and concern around vaccine side-effects. It is unclear if these challenges led to a lower uptake than seen in other school-based vaccine programmes (40.6%). Key messages • The implementation of the COVID-19 vaccine in children aged 12-15 years presented unique challenges however the school-based delivery model was deemed a success. • Further investigation into the uptake is warranted.